These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 38203663)

  • 1. Development and Characterization of
    Bolzati C; Gobbi C; Ferro-Flores G; Turato S; Ocampo-Garcia B; Carpanese D; Marzano C; Spolaore B; Fracasso G; Rosato A; Meléndez-Alafort L
    Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical translation of a PSMA inhibitor for
    Ferro-Flores G; Luna-Gutiérrez M; Ocampo-García B; Santos-Cuevas C; Azorín-Vega E; Jiménez-Mancilla N; Orocio-Rodríguez E; Davanzo J; García-Pérez FO
    Nucl Med Biol; 2017 May; 48():36-44. PubMed ID: 28193503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Full preclinical validation of the 123I-labeled anti-PSMA antibody fragment ScFvD2B for prostate cancer imaging.
    Frigerio B; Franssen G; Luison E; Satta A; Seregni E; Colombatti M; Fracasso G; Valdagni R; Mezzanzanica D; Boerman O; Canevari S; Figini M
    Oncotarget; 2017 Feb; 8(7):10919-10930. PubMed ID: 28051996
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical dosimetric studies of
    Meléndez-Alafort L; Ferro-Flores G; Santos-Cuevas C; Ocampo-García B; Turato S; Fracasso G; Bolzati C; Rosato A; De Nardo L
    Med Phys; 2021 Jul; 48(7):4064-4074. PubMed ID: 33966284
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of
    Carpanese D; Ferro-Flores G; Ocampo-Garcia B; Santos-Cuevas C; Salvarese N; Figini M; Fracasso G; De Nardo L; Bolzati C; Rosato A; Meléndez-Alafort L
    Sci Rep; 2020 Jun; 10(1):9313. PubMed ID: 32518372
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical Evaluation and First Patient Application of 99mTc-PSMA-I&S for SPECT Imaging and Radioguided Surgery in Prostate Cancer.
    Robu S; Schottelius M; Eiber M; Maurer T; Gschwend J; Schwaiger M; Wester HJ
    J Nucl Med; 2017 Feb; 58(2):235-242. PubMed ID: 27635024
    [TBL] [Abstract][Full Text] [Related]  

  • 7. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of Radiation dosimetry of
    Zhang J; Zhang J; Xu X; Lu L; Hu S; Liu C; Cheng J; Song S; Zhang Y; Shi LQ
    Sci Rep; 2020 Mar; 10(1):4179. PubMed ID: 32144340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Theranostic Optimization of PSMA-GCK01 Does Not Compromise the Imaging Characteristics of [
    Mamlins E; Scharbert L; Cardinale J; Krotov M; Winter E; Rathke H; Strodel B; Ankrah AO; Sathekge M; Haberkorn U; Kratochwil C; Giesel FL
    Mol Imaging Biol; 2024 Feb; 26(1):81-89. PubMed ID: 38066252
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis, radiolabeling and biological evaluation of new urea-based peptides targeting prostate specific membrane antigen.
    Mosayebnia M; Hajimahdi Z; Beiki D; Rezaeianpour M; Hajiramezanali M; Geramifar P; Sabzevari O; Amini M; Hatamabadi D; Shahhosseini S
    Bioorg Chem; 2020 Jun; 99():103743. PubMed ID: 32217372
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Xu X; Zhang J; Hu S; He S; Bao X; Ma G; Luo J; Cheng J; Zhang Y
    Nucl Med Biol; 2017 May; 48():69-75. PubMed ID: 28273495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-PSMA
    Frigerio B; Morlino S; Luison E; Seregni E; Lorenzoni A; Satta A; Valdagni R; Bogni A; Chiesa C; Mira M; Canevari S; Alessi A; Figini M
    J Exp Clin Cancer Res; 2019 Jul; 38(1):326. PubMed ID: 31337429
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [
    Vats K; Chakraborty A; Rakshit S; Damle A; Sarma HD; Satpati D
    Nucl Med Biol; 2023; 118-119():108331. PubMed ID: 36933456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dosimetry estimation and preliminary clinical application of [
    Yang H; Gao Z; Xu X; Liu C; Hu S; Zhang J; Song S
    Ann Nucl Med; 2023 Jan; 37(1):60-69. PubMed ID: 36346503
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of a New
    Farahani AM; Maleki F; Sadeghzadeh N; Abediankenari S; Abedi SM; Erfani M
    Anticancer Agents Med Chem; 2020; 20(14):1695-1703. PubMed ID: 32560611
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic sensitivity of Tc-99m HYNIC PSMA SPECT/CT in prostate carcinoma: A comparative analysis with Ga-68 PSMA PET/CT.
    Lawal IO; Ankrah AO; Mokgoro NP; Vorster M; Maes A; Sathekge MM
    Prostate; 2017 Aug; 77(11):1205-1212. PubMed ID: 28649735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PSMA-GCK01: A Generator-Based
    Cardinale J; Giesel FL; Wensky C; Rathke HG; Haberkorn U; Kratochwil C
    J Nucl Med; 2023 Jul; 64(7):1069-1075. PubMed ID: 36759199
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Generation and characterization of nanobodies targeting PSMA for molecular imaging of prostate cancer.
    Evazalipour M; D'Huyvetter M; Tehrani BS; Abolhassani M; Omidfar K; Abdoli S; Arezumand R; Morovvati H; Lahoutte T; Muyldermans S; Devoogdt N
    Contrast Media Mol Imaging; 2014; 9(3):211-20. PubMed ID: 24700748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen for molecular imaging of prostate cancer.
    Hillier SM; Maresca KP; Lu G; Merkin RD; Marquis JC; Zimmerman CN; Eckelman WC; Joyal JL; Babich JW
    J Nucl Med; 2013 Aug; 54(8):1369-76. PubMed ID: 23733925
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Receptor-Targeted Peptide Conjugates Based on Diphosphines Enable Preparation of
    Pham TT; Hungnes IN; Rivas C; Cleaver J; Firth G; Blower PJ; Sosabowski J; Cook GJR; Livieratos L; Young JD; Pringle PG; Ma MT
    J Nucl Med; 2024 Jul; 65(7):1087-1094. PubMed ID: 38844360
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.